FI3371316T3 - Rokotteita hepatiitti b -virusta vastaan - Google Patents

Rokotteita hepatiitti b -virusta vastaan Download PDF

Info

Publication number
FI3371316T3
FI3371316T3 FIEP16791573.5T FI16791573T FI3371316T3 FI 3371316 T3 FI3371316 T3 FI 3371316T3 FI 16791573 T FI16791573 T FI 16791573T FI 3371316 T3 FI3371316 T3 FI 3371316T3
Authority
FI
Finland
Prior art keywords
hbv
protein
viral vector
nucleotide sequence
hbc
Prior art date
Application number
FIEP16791573.5T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Thomas Monath
Katherine Cohen
Vera Baumgartl-Strasser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FI3371316T3 publication Critical patent/FI3371316T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP16791573.5T 2015-11-04 2016-11-03 Rokotteita hepatiitti b -virusta vastaan FI3371316T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
FI3371316T3 true FI3371316T3 (fi) 2023-01-13

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16791573.5T FI3371316T3 (fi) 2015-11-04 2016-11-03 Rokotteita hepatiitti b -virusta vastaan

Country Status (20)

Country Link
US (2) US11214598B2 (enExample)
EP (2) EP3371316B1 (enExample)
JP (3) JP6914950B2 (enExample)
KR (2) KR102832178B1 (enExample)
CN (2) CN108779472B (enExample)
AU (2) AU2016348675B2 (enExample)
CA (1) CA3003557A1 (enExample)
DK (1) DK3371316T3 (enExample)
ES (1) ES2934698T3 (enExample)
FI (1) FI3371316T3 (enExample)
HR (1) HRP20221474T1 (enExample)
HU (1) HUE060648T2 (enExample)
IL (2) IL259077B2 (enExample)
LT (1) LT3371316T (enExample)
MX (2) MX2018005569A (enExample)
PL (1) PL3371316T3 (enExample)
PT (1) PT3371316T (enExample)
SG (1) SG11201803474UA (enExample)
SI (1) SI3371316T1 (enExample)
WO (1) WO2017076988A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
PL3218504T3 (pl) 2014-11-13 2021-02-08 Université De Genève Trójsegmentowe arenawirusy jako wektory szczepionkowe
WO2016198531A2 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CN108779472B (zh) * 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
US11266727B2 (en) 2015-11-12 2022-03-08 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
FI3526323T3 (fi) 2016-10-14 2023-06-06 Prec Biosciences Inc Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
MA56524A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
KR20220041080A (ko) * 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
JP7398556B2 (ja) 2019-09-30 2023-12-14 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖワクチン及びｈｂｖを治療する方法
CN114981443A (zh) * 2019-11-07 2022-08-30 巴塞尔大学 作为载体的沙粒病毒
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
WO2022200373A2 (en) 2021-03-23 2022-09-29 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
WO2022226242A1 (en) * 2021-04-21 2022-10-27 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
BR9915942A (pt) * 1998-12-04 2001-08-21 Biogen Inc Patìculas de antìgeno de núcleo de hbv com componentes imunogênicos múltiplos ligados através de ligantes de peptìdeo
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2006125983A1 (en) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
NZ594510A (en) * 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
PH12013501683A1 (en) * 2011-02-12 2019-07-17 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis b infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
KR102195196B1 (ko) 2012-01-24 2020-12-28 샌포드 헬스 종양원성 바이러스성 폴리펩티드 양성 종양 치료용 폴리뉴클레오티드
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
US10533159B2 (en) 2014-09-22 2020-01-14 Regents Of The University Of Minnesota Pichinde virus reverse genetics systems and methods of use
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
PL3218504T3 (pl) * 2014-11-13 2021-02-08 Université De Genève Trójsegmentowe arenawirusy jako wektory szczepionkowe
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
WO2016198531A2 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
WO2017068190A1 (en) 2015-10-23 2017-04-27 Institut Pasteur Recombinant mopeia virus and vaccine platform
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
US11266727B2 (en) 2015-11-12 2022-03-08 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
MX2018013956A (es) 2016-05-18 2019-07-04 Hookipa Biotech Gmbh Virus pichinde de tres segmentos como vectores de vacunas.
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
US20200113995A1 (en) 2017-04-07 2020-04-16 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
EP3371316B1 (en) 2022-10-19
MX2023013140A (es) 2023-11-28
US20180319845A1 (en) 2018-11-08
CA3003557A1 (en) 2017-05-11
HUE060648T2 (hu) 2023-04-28
SI3371316T1 (sl) 2023-02-28
IL259077B1 (en) 2024-08-01
KR20180082485A (ko) 2018-07-18
EP3371316A1 (en) 2018-09-12
MX2018005569A (es) 2018-12-19
KR102832178B1 (ko) 2025-07-11
IL259077A (en) 2018-06-28
JP7777907B2 (ja) 2025-12-01
NZ741950A (en) 2023-10-27
WO2017076988A1 (en) 2017-05-11
JP2021182922A (ja) 2021-12-02
JP2018536433A (ja) 2018-12-13
ES2934698T3 (es) 2023-02-24
AU2023200108B2 (en) 2025-08-28
HK1255847A1 (en) 2019-08-30
AU2023200108A1 (en) 2023-02-16
NZ781654A (en) 2025-06-27
KR20250107977A (ko) 2025-07-14
IL259077B2 (en) 2024-12-01
CN115948467A (zh) 2023-04-11
EP4177348A1 (en) 2023-05-10
US11214598B2 (en) 2022-01-04
AU2016348675A1 (en) 2018-05-17
LT3371316T (lt) 2022-11-25
CN108779472A (zh) 2018-11-09
JP2024010027A (ja) 2024-01-23
SG11201803474UA (en) 2018-05-30
BR112018009032A2 (pt) 2018-11-06
AU2016348675B2 (en) 2022-11-17
HRP20221474T1 (hr) 2023-01-06
PL3371316T3 (pl) 2023-02-13
JP6914950B2 (ja) 2021-08-11
BR112018009032A8 (pt) 2019-02-26
IL314371A (en) 2024-09-01
DK3371316T3 (da) 2023-01-23
CN108779472B (zh) 2022-09-09
US20220073568A1 (en) 2022-03-10
PT3371316T (pt) 2022-11-17

Similar Documents

Publication Publication Date Title
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP2021182922A5 (enExample)
JP2018536433A5 (enExample)
Rodrigues et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology
US10925946B2 (en) Vaccination methods
HRP20211015T1 (hr) Cjepivo protiv citomegalovirusa (cmv)
JP2017503482A5 (enExample)
JP2017527557A5 (enExample)
Dietzschold et al. New approaches to the prevention and eradication of rabies
JP2017535267A5 (enExample)
CN104968782B (zh) 利用人副流感2型病毒载体的疫苗
JP2017522907A5 (enExample)
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
CN110904153A (zh) 表达非洲猪瘟病毒p12或p17蛋白的重组猪繁殖与呼吸综合征病毒的构建方法及其应用
Li et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice
Maamary et al. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice
Zhang et al. Virus-like vesicles based on Semliki forest virus-containing rabies virus glycoprotein make a safe and efficacious rabies vaccine candidate in a mouse model
Lawrence et al. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses
Wang et al. Parainfluenza virus 5 is a next‐generation vaccine vector for human infectious pathogens
Shoja et al. Formation of self‐assembled triple‐layered rotavirus‐like particles (tlRLPs) by constitutive co‐expression of VP2, VP6, and VP7 in stably transfected high‐five insect cell lines
Lundstrom Self-replicating RNA viral vectors in vaccine development and gene therapy
Chapman et al. Assessment of an LSDV-vectored vaccine for heterologous prime-boost immunizations against HIV
Meseda et al. Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines
US20160279229A9 (en) Viral Vaccine Vectors
Reguzova et al. A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge